GlycoEra

Executive Summary

GlycoEra is a Swiss precision immunology company founded in 2019, leveraging a best-in-class platform to selectively degrade disease-driving proteins in autoimmune conditions. By targeting specific circulating proteins early in the disease course, GlycoEra aims to overcome the limitations of current broad-acting therapies that have narrow therapeutic indices and are restricted to late-line use. The company's approach represents a paradigm shift toward early, precise intervention, potentially improving outcomes for patients with autoimmune diseases. While still in early stages without disclosed funding or pipeline details, GlycoEra's platform has the potential to address significant unmet medical needs. The company is privately held and based in Schlieren, Switzerland, with a focus on small molecule degraders.

Upcoming Catalysts (preview)

• H2 2026Lead Program IND Filing30% success
• H1 2026Series A Financing Announcement50% success
• H2 2026Preclinical Proof-of-Concept Data Publication40% success